Profile data is unavailable for this security.
About the company
Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.
- Revenue in USD (TTM)970.40k
- Net income in USD-33.19m
- Incorporated2005
- Employees41.00
- LocationVistagen Therapeutics Inc343 ALLERTON AVENUESOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 577-3600
- Websitehttps://www.vistagen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aileron Therapeutics Inc | 0.00 | -25.22m | 82.33m | 15.00 | -- | 1.47 | -- | -- | -3.25 | -3.25 | 0.00 | 4.67 | 0.00 | -- | -- | 0.00 | -40.88 | -65.99 | -43.02 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Armata Pharmaceuticals Inc | 3.72m | -67.04m | 84.13m | 66.00 | -- | -- | -- | 22.62 | -1.95 | -1.95 | 0.0893 | -1.28 | 0.0355 | -- | 0.7532 | 56,348.48 | -64.00 | -59.78 | -385.50 | -72.70 | -- | -- | -1,802.72 | -1,113.72 | -- | -1.99 | 1.71 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Agenus Inc | 159.63m | -223.67m | 84.24m | 389.00 | -- | -- | -- | 0.5277 | -11.27 | -11.27 | 8.03 | -11.42 | 0.4723 | -- | 154.98 | 410,357.30 | -68.45 | -55.02 | -281.52 | -115.31 | 99.51 | -- | -144.94 | -102.92 | -- | -0.9185 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| CytomX Therapeutics Inc | 119.57m | 11.09m | 85.15m | 120.00 | 7.95 | -- | 6.56 | 0.7121 | 0.1371 | 0.1371 | 1.45 | -0.3997 | 0.6491 | -- | 51.12 | 996,408.30 | 6.02 | -21.53 | 26.34 | -32.32 | -- | -- | 9.27 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Clearside Biomedical Inc | 7.52m | -33.46m | 85.21m | 30.00 | -- | -- | -- | 11.33 | -0.497 | -0.497 | 0.1119 | -0.3785 | 0.2058 | -- | 59.01 | 250,800.00 | -91.51 | -63.57 | -107.97 | -81.77 | 95.06 | -- | -444.66 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
| Vistagen Therapeutics Inc | 970.40k | -33.19m | 87.43m | 41.00 | -- | 0.8106 | -- | 90.10 | -1.53 | -1.53 | 0.0386 | 3.87 | 0.0151 | -- | -- | 24,882.05 | -51.63 | -62.84 | -56.12 | -68.03 | -- | -- | -3,420.44 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| Chimerix Inc | 144.00k | -84.70m | 88.74m | 72.00 | -- | 0.5704 | -- | 616.27 | -0.9507 | -0.9507 | 0.0016 | 1.74 | 0.0007 | -- | 1.86 | 2,000.00 | -40.37 | -30.45 | -44.33 | -34.09 | 10.42 | -- | -58,820.14 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Monopar Therapeutics Inc | 0.00 | -6.47m | 89.09m | 10.00 | -- | 12.03 | -- | -- | -1.99 | -1.99 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -88.32 | -54.07 | -112.04 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -48.88m | 89.64m | 63.00 | -- | 0.4183 | -- | -- | -0.9662 | -0.9662 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -20.38 | -21.16 | -21.39 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.30m | 90.05m | 12.00 | -- | 10.96 | -- | -- | -0.3306 | -0.3306 | 0.00 | 0.6316 | 0.00 | -- | -- | 0.00 | -41.44 | -56.31 | -42.99 | -77.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 26.73 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 90.56m | -- | 5.25 | 0.1832 | 46.83 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| Ovid Therapeutics Inc | 567.53k | -29.75m | 92.26m | 40.00 | -- | 1.04 | -- | 162.57 | -0.4218 | -0.4218 | 0.008 | 1.25 | 0.0045 | -- | -- | 14,188.25 | -23.39 | -20.78 | -25.86 | -23.27 | -- | -- | -5,241.56 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
Data as of Nov 08 2024. Currency figures normalised to Vistagen Therapeutics Inc's reporting currency: US Dollar USD
45.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Jun 2024 | 2.00m | 7.39% |
| StemPoint Capital LPas of 30 Jun 2024 | 1.85m | 6.83% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.78m | 6.59% |
| Commodore Capital LPas of 30 Jun 2024 | 1.58m | 5.82% |
| Great Point Partners LLCas of 30 Jun 2024 | 1.53m | 5.65% |
| Nantahala Capital Management LLCas of 30 Jun 2024 | 1.52m | 5.61% |
| Sphera Funds Management Ltd.as of 30 Jun 2024 | 808.55k | 2.99% |
| Citadel Advisors LLCas of 30 Jun 2024 | 614.98k | 2.27% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 398.04k | 1.47% |
| Armistice Capital LLCas of 30 Jun 2024 | 300.00k | 1.11% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
